货号 | AF-206-SP |
别名 | B cell stimulatory factor-2; B-cell differentiation factor; BSF-2; BSF2CTL differentiation factor; CDF; HGFHSFIFNB2Hybridoma growth factor; IFN-beta-2; IL6; IL-6; IL-6B-cell stimulatory factor 2; Interferon beta-2; interleukin 6 (interferon, beta 2); interleukin BSF-2; interleukin-6; MGI-2A | 全称 | Interleukin 6 |
反应种属 | Human |
应用 | Western Blot,Immunocytochemistry,Neutralization |
目标/特异性 | Detects human IL-6 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant mouse IL-6 is observed. |
使用方法 | Western Blot: 0.2 µg/mL Immunocytochemistry: 5-15 µg/mL Neutralization: Measured by its ability to neutralize IL‑6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. Nordan, R.P. and M. Potter (1986) Science 233:566. The Neutralization Dose (ND50) is typically 15-45 ng/mL in the presence of 2.5 ng/mL Recombinant Human IL‑6. |
来源 | Polyclonal Goat IgG |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 3569 (Human); 16193 (Mouse); 24498 (Rat); 399500 (Porcine); 280826 (Bovine); 403985 (Canine); 100034196 (Equine); 493687 (Feline); 100008733 (Rabbit) |
应用文献 | |
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ | |
纯化方式 | Antigen Affinity-purified |
免疫原 | E. coli-derived recombinant human IL-6 Pro29-Met212 Accession # P05231 |
内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
生物活性 | Human |
标记 | Unconjugated |
溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
背景 | Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is essential for the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22-28 kDa phosphorylated and variably glycosylated molecule (1-4). Mature human IL-6 is 183 amino acids (aa) in length and shares 41% aa sequence identity with mouse and rat IL-6 (5). Alternate splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties (6-9). Human IL-6 is equally active on mouse and rat cells (10). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (11). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (12). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL-6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 13). |
运输条件 | Blue Ice |
存放说明 | 4℃ |
参考文献 |
|
Detection of Human IL‑6 by Western Blot. Western blot shows lysates of human peripheral blood mononuclear cells (PBMC) untreated (-) or treated (+) with PHA. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Human IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-206-NA) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for IL‑6 at approximately 20-22 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1. | |
IL‑6 in Human PBMCs. IL‑6 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) treated with LPS and monensin using Goat Anti-Human IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-206-NA) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells. | |
Cell Proliferation Induced by IL‑6 and Neutralization by Human IL‑6 Antibody. Recombinant Human IL‑6 (Catalog # 206-IL) stimulates proliferation in the T1165.85.2.1 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL‑6 (2.5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-206-NA). The ND50 is typically 15-45 ng/mL. |